Board Of Directors

Mr Charles Wang Chong Guang
Non-Executive Chairman

Mr Wang has many years of experience in corporate finance, mergers and acquisitions, and financial management, of which more than 20 years have been spent with publicly-listed and private companies in the healthcare industry.

Mr Wang is the Group Chief Executive Officer of the Luye Medical Group. He joined Luye Medical Group as the Chief Financial Officer in February 2015 and subsequently became the Group Chief Executive Officer in April 2017. From February 2015 to December 2016, he was also concurrently holding the appointment of Group Vice President of Luye Pharma, where he had overall responsibility for Luye Pharma's merger & acquisitions and capital market activities, including equity and debt-related issuances outside of the PRC.

Mr Wang began his career with Kingston Smith Chartered Accountants in London, United Kingdom from 1988 to 1993, where his last held position was Assistant Audit Manager. He then joined Coopers & Lybrand (subsequently merged with Price Waterhouse to become PriceWaterhouse Coopers) in Hong Kong in October 1993 as a Corporate Finance Manager. In December 1995, Mr Wang joined Hanson Pacific Limited, the Asia Pacific headquarters of Hanson Plc, an industrial conglomerate previously listed in the United Kingdom, as Finance Director. In June 1999, he joined Asia Renal Care Limited, a healthcare services company which specialises in providing kidney dialysis services in the Asia Pacific region, as Chief Financial Officer. In December 2008, he joined Tongjitang Chinese Medicine Limited, a company that specialises in the manufacturing and distribution of modern Chinese medicine and which was previously listed on the New York Stock Exchange, as Chief Financial Officer. From November 2010 to January 2012, he was appointed as the Chief Financial Officer of Trauson Holdings Company Limited, an orthopaedic device manufacturing company previously listed on the Hong Kong Stock Exchange. Subsequently from July 2012 to February 2015, he served as the Chief Financial Officer of China NT Pharma Group Company Limited, a company listed on the Hong Kong Stock Exchange which specializes in the manufacturing and distribution of pharmaceutical products.

As the Chief Financial Officer of the companies that Mr Wang served at, Mr Wang was responsible for, among others, finance, mergers & acquisitions, information technology, company secretarial and investor relations functions of these companies.

Mr Wang obtained a Bachelor's Degree in Economics (Honours) from the University of Leeds in 1988. He is also a member of the Institute of Chartered Accountants of England and Wales since 1991.

Ms Alice Ng Bee Yee
Independent Director

Ms Ng has more than 20 years of experience in the corporate finance sector, where she was involved in initial public offerings and reverse takeover transactions, as well as other financial advisory transactions and continuing sponsorships. Since June 2022, Ms Ng is the Head of Finance at Golden Energy And Resources Pte. Ltd. (formerly known as Golden Energy and Resources Limited), a company previously listed on the Mainboard of the Singapore Exchange. Prior to this, Ms Ng was Director of Continuing Sponsorship at ZICO Capital Pte. Ltd., and advised Catalist-listed companies on compliance with the SGX-Catalist Rules. Ms Ng had also held various positions as Director of Corporate Finance / Continuing Sponsorship in Canaccord Genuity Singapore Pte. Ltd. (formerly known as Collins Stewart Pte. Limited), Director of Corporate Finance in CIMB Bank Berhad, Assistant Vice President (Capital Market Group) in Phillip Securities Pte Ltd, and Assistant Vice President (Corporate Finance Department) in Hong Leong Finance Limited. She was also involved in compliance and audit work from July 1998 to March 2001.

Ms Ng graduated from Nanyang Technological University with a Bachelor of Accountancy in 1998.

Mr Chua Keng Woon
Independent Director

Mr Chua has over 16 years of experience in the banking and finance industry. He served as an advisor to Secured Capital Singapore Pte Ltd, a company engaged in mezzanine financing services, from January to November 2018. From 2008 to 2016, Mr Chua was with Canaccord Genuity Singapore Pte Ltd (formerly known as Collins Stewart Pte. Limited). He last held the position of Senior Director, Equity Capital Market and was primarily involved in corporate advisory and fund raising activities for companies. Prior to that, Mr Chua had held various posts as Associate Director of Capital Market Group in Phillip Securities Pte Ltd, Assistant Vice President, Corporate Finance in Hong Leong Finance Limited, Manager, Corporate Finance in UOB Asia Limited, Manager in Capital Equity Markets in DBS Bank Limited, as well as Senior Officer - Inspectorate Department in the Stock Exchange of Singapore. He is also an independent director of Hai Leck Holdings Ltd.

Mr Chua graduated from Nanyang Technological University with a Bachelor of Business Degree majoring in Financial Analysis in 1996. He is a CFA charterholder and member of CFA Institute.

Mr Leong Yew Meng
Independent Director

Mr Leong brings with him more than 30 years of experience in the healthcare industry.

Mr Leong started his healthcare career in 1989 at Singapore General Hospital, before he went on to serve as Chief Operating Officer at the National University Hospital from 1994 to 2000. He joined Thomson Medical Group as its Group Chief Executive Officer in 2000. In 2002, he was appointed Chief Executive Officer of Woodbridge Hospital/Institute of Mental Health, a role he held from 2002 to 2011. In 2009, he was concurrently appointed Chief Executive Officer of National Healthcare Group Polyclinics and stayed on until 2014.

In 2016, Mr Leong was appointed Chief Executive Officer (Greater China) and had provided leadership for Parkway Pantai Ltd's operations in China and Hong Kong including its primary care clinics in Shanghai, Beijing, Suzhou and Hong Kong and development of new hospital projects in Chengdu, Hong Kong, Nanjing and Shanghai. He left Parkway Pantai Ltd in 2017 to join Shanghai Fosun Hospital Investment (Group) Co. Ltd. as its Chief Executive Officer to spearhead the operations and management of its eight hospitals and several new hospital development projects in various cities in China. He also served as a board member of United Family Health, a leading high-end premier healthcare brand in China with seven hospitals and more than 20 clinics in Beijing, Shanghai, Tianjin, Guangzhou, Qingdao, and Hainan Island. He left Shanghai Fosun Hospital Investment (Group) Co. Ltd. in February 2019 to return to Singapore.

Mr Leong has a Bachelor of Mechanical Engineering degree and a Master of Business Administration degree (MBA) from the National University of Singapore. He also attended the Advanced Management Program at Wharton School, University of Pennsylvania.

Ms Aona Liu
Non-Executive Director

Ms Liu started her career in strategic consulting and has experience in mergers & acquisitions and healthcare management across Singapore, Japan, Australia, and China. She is currently the Executive Chairperson of Luye Medical Group group of companies, the hospital and healthcare services platform of Luye Life Sciences Group Ltd. Luye Medical Group group of companies provides medical services with a focus on specialties such as oncology, cardiology, mental health and rehabilitation.

She is also the founding CEO of Philosojoy Singapore Pte. Ltd., a company established to invest in artistic areas and to preserve and promote Asian art, culture and heritage.

Ms Liu holds a Bachelor of Arts in Economics (Honours) and a Master of Arts in Economics (Honours) from the University of Edinburgh and a Master of Science in International Healthcare Management from Imperial College London.